Pharmaceutical

Medpace's 2024 Financial Report Medpace Financial statements Medpace’s 2024 financial report shows impressive growth, with a 50% surge in Q4 net profit and a 43% annual increase. The company forecasts 2025 revenue between $2.11B and $2.21B, continuing strong performance in the global CRO industry.
Pharmaceutical Giants Ranking 2024 Market Trend Merck Bristol Myers Squibb AstraZeneca Pfizer Roche Explore the top pharmaceutical giants of 2024, including Merck, Johnson & Johnson, and more. Learn about their revenue, profits, R&D investments, and market value in this detailed ranking report.
SMA: Three Major Drugs Developed in Five Years SMA Spinal Muscular Atrophy SMA (Spinal Muscular Atrophy) has led to significant drug advancements. This article explores the development of three major SMA treatments—Spinraza, Evrysdi, and Zolgensma—highlighting their benefits, challenges, and market impact.
Semaglutide: Daily Earnings of $580 Million Semaglutide Novo Nordisk Weight loss drugs Semaglutide's impressive sales growth has made Novo Nordisk a pharmaceutical powerhouse, with daily earnings of $580 million. Discover how Semaglutide is transforming the weight-loss and diabetes markets, surpassing expectations in 2024.
2024 FDA Issued CRLs FDA Astellas Daiichi Sankyo AbbVie Novo Nordisk Johnson & Johnson The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
JPM 2025: China's Biopharmaceutical Surprises, Bubbles, and Landing JPM The recent JPM conference in San Francisco witnessed significant discussions in the biotech sector, with Chinese biotech companies making notable strides despite a challenging market environment.
Trump's Presidency: Impact on the U.S. Biopharma Industry FDA NIH IRA Biosecure Act Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
What New Products and Models Are JPM Multinationals Focusing On in 2025? JPM Discover the latest trends in the 2025 biopharma industry! From Johnson & Johnson's $14.6B acquisition to Eli Lilly's impressive revenue growth, major M&As, and cutting-edge therapies across oncology, neuroscience, and ophthalmology reshaping global pharma.
Fat Loss Without Muscle Loss: A New Frontier in Weight Management Weight loss Ascletis Pharma Explore the latest advancements in weight loss drugs focusing on fat reduction and muscle preservation. Learn about promising treatments like ASC47, ActRIIA/B inhibitors, and their impact on obesity and muscle mass.
Big Pharma -Waiting for the other Shoe to Drop Biotech AbbVie Pfizer BioNTech Novo Nordisk Eli Lilly Explore the shifting landscape of big pharma as clinical trial results, patent cliffs, and innovative therapies shape 2025. Discover how giants like Eli Lilly, Pfizer, and Novo Nordisk navigate challenges and opportunities in weight loss, oncology, and vaccines.

< Pre 1...57 58 596061 62 63...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles